Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy
NCT03933956Phase 3Terminated
- Sponsor
- Singapore General Hospital
- Start
- Jan 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of empagliflozin in diabetic nephropathy (DN), sponsored by Singapore General Hospital. Primary endpoints: Change in lipid metabolome signature at 30 days, Change in ketone signature at 30 days and 1 more. Started Jan 2020; status: terminated.
02
Drugs
empagliflozin
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT03933956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933956.